Industry Briefs

Recombinant DNA Biodegradable Pesticide Mycogen Corp. has begun the first large-scale field trials in the U.S. of a pesticide developed through recombinant DNA techniques. The pesticide, called MVP, is a protein produced by a strain of the Bacillus thuringiensis (B.t.) bacterium. The San Diego firm inserts the gene that produces the B.t. toxin into another bacterium called Pseudomonas fluorescens. Then the new bacteria are killed, and a "biocapsule" forms around the toxin, which is fatal to lea

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Recombinant DNA Biodegradable Pesticide Mycogen Corp. has begun the first large-scale field trials in the U.S. of a pesticide developed through recombinant DNA techniques. The pesticide, called MVP, is a protein produced by a strain of the Bacillus thuringiensis (B.t.) bacterium. The San Diego firm inserts the gene that produces the B.t. toxin into another bacterium called Pseudomonas fluorescens. Then the new bacteria are killed, and a "biocapsule" forms around the toxin, which is fatal to leaf-eating insects like caterpillars. With initial MVP spraying in Florida and Texas, Mycogen hopes to extend trials to a total of 17 states. Since 1988, Mycogen has been selling its first bioinsecticide, M-One, also based on a B.t. strain, to combat the Colorado potato beetle and other pests. Both biopesticides are biodegradable and have no effects on mammals, Mycogen researchers say. They add that because the effects of these poisons are so complex, crop ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Graphic of amino acid chains folded into proteins

Expi293™ PRO Expression System: Higher Yields Across a Wider Variety of Proteins

Thermo Fisher Logo